Evidence map›Paper›PMID 37197821›Full record

ArticleBMJ open2023

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK.

Benjamin M Jacobs, Luisa Schalk, Angie Dunne, Antonio Scalfari, Ashwini Nandoskar, Bruno Gran, Charles A Mein, Charlotte Sellers, Cord Spilker, David Rog and 47 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors.

Benjamin M JacobsPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.ORCID 0000-0002-6023-6010
Luisa SchalkPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Angie DunneLeeds Centre for Neurosciences, Leeds teaching Hospitals NHS Trust, Leeds, UK.
Antonio ScalfariCentre of Neuroscience, Department of Medicine, Imperial College London, London, UK.
Ashwini NandoskarHillingdon and Imperial NHS Trust, London, UK.
Bruno GranDepartment of Neurology, Nottingham University Hospitals NHS Trust, Mental Health and Clinical Neuroscience Academic Unit, University of Nottingham School of Medicine, Nottingham, UK.
Charles A MeinBarts and the London Genome Centre, Queen Mary University of London, London, UK.
Charlotte SellersPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Cord SpilkerBradford Teaching Hospital Foundation Trust, Bradford, UK.
David RogManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Trust, Manchester, UK.
Elisa VisentinResearch and Innovation, Queen's Hospital, BHRUT, London, UK.
Elizabeth Lindsey BezzinaKings College Hospital and Lewisham and Greenwich NHS Trusts, London, UK.
Emeka UzochukwuDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Emma TallantyreDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Eva WozniakBarts and the London Genome Centre, Queen Mary University of London, London, UK.
Eve SacreLeeds Centre for Neurosciences, Leeds teaching Hospitals NHS Trust, Leeds, UK.
Ghaniah Hassan-SmithUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Helen L FordLeeds Centre for Neurosciences, Leeds teaching Hospitals NHS Trust, Leeds, UK.
Jade HarrisNorthern Care Alliance NHS Trust, Manchester, UK.
Joan BradleyHillingdon and Imperial NHS Trust, Uxbridge, UK.
Joshua BreedonPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Judith BrookeNorthern Care Alliance NHS Trust, Manchester, UK.
Karim L KreftDepartment of Neurology, University Hospital of Wales, Cardiff, UK.
Katherine Tuite DaltonPopulation Data Science, Swansea University Medical School, Swansea, UK.
Katila GeorgePreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Maria PapachatzakiMid and South Essex NHS Foundation Trust, Southend-on-Sea, UK.
Martin O'MalleyLeeds Centre for Neurosciences, Leeds teaching Hospitals NHS Trust, Leeds, UK.
Michelle PeterPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Miriam MattoscioDepartment of neuroscience, Queen's Hospital, BHRUT NHS Trust, Romford, UK.
Neisha RhuleQueen Elizabeth Hospital (Lewisham and Greenwich NHS Trust), London, UK.
Nikos EvangelouDepartment of Neurology, Nottingham University Hospitals NHS Trust; Mental Health and Clinical Neuroscience Academic Unit, University of Nottingham School of Medicine, Nottingham, UK.
Nimisha VinodNorthern Care Alliance NHS Trust, Manchester, UK.
Outi QuinnBradford Teaching Hospital Foundation Trust, Bradford, UK.
Ramya ShamjiResearch and Innovation, Queen's Hospital, BHRUT, London, UK.
Rashmi KaimalPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Rebecca BoultonDepartment of Neurology, Nottingham University Hospitals NHS Trust; Mental Health and Clinical Neuroscience Academic Unit, University of Nottingham School of Medicine, Nottingham, UK.
Riffat TanveerLancashire Teaching Hospital NHS Foundation Trust, Preston, UK.
Rod MiddletonPopulation Data Science, Swansea University Medical School, Swansea, UK.
Roxanne MurrayPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Ruth BellfieldBradford Teaching Hospital Foundation Trust, Bradford, UK.
Sadid HoquePreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Shakeelah PatelLancashire Teaching Hospital NHS Foundation Trust, Preston, UK.
Sonia RajLancashire Teaching Hospital NHS Foundation Trust, Preston, UK.
Stephanie GumusMid and South Essex NHS Foundation Trust, Southend-on-Sea, UK.
Stephanie MitchellNorthern Care Alliance NHS Trust, Manchester, UK.
Stephen SawcerUniversity of Cambridge, Department of Clinical Neuroscience, Addenbrookes Hospital, Hills Road, Cambridge, UK.
Tarunya ArunUniversity Hospitals of Coventry and Warwickshire, Coventry, UK.
Tatiana PogrebanResearch and Innovation, Queen's Hospital, BHRUT, London, UK.
Terri-Louise BrownPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Thamanna BegumPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Veronica AntoineNorthern Care Alliance NHS Trust, Manchester, UK.
Waqar RashidSt George's University Hospitals NHS Foundation Trust, London, UK.
Alastair J NoycePreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Eli SilberKings College Hospital and Lewisham and Greenwich NHS Trusts, London, UK.
Huw MorrisDepartment of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.
Gavin GiovannoniPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Ruth DobsonPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK ruth.dobson@qmul.ac.uk.ORCID 0000-0002-2993-585X

Funding

Medical Research Council MR/V028766/1
6 · The paper itself

Abstract

purposeGenetic studies of multiple sclerosis (MS) susceptibility and severity have focused on populations of European ancestry. Studying MS genetics in other ancestral groups is necessary to determine the generalisability of these findings. The genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis (ADAMS) project aims to gather genetic and phenotypic data on a large cohort of ancestrally-diverse individuals with MS living in the UK.

participantsAdults with self-reported MS from diverse ancestral backgrounds. Recruitment is via clinical sites, online (https://app.mantal.co.uk/adams) or the UK MS Register. We are collecting demographic and phenotypic data using a baseline questionnaire and subsequent healthcare record linkage. We are collecting DNA from participants using saliva kits (Oragene-600) and genotyping using the Illumina Global Screening Array V.3. FINDINGS TO DATE: As of 3 January 2023, we have recruited 682 participants (n=446 online, n=55 via sites, n=181 via the UK MS Register). Of this initial cohort, 71.2% of participants are female, with a median age of 44.9 years at recruitment. Over 60% of the cohort are non-white British, with 23.5% identifying as Asian or Asian British, 16.2% as Black, African, Caribbean or Black British and 20.9% identifying as having mixed or other backgrounds. The median age at first symptom is 28 years, and median age at diagnosis is 32 years. 76.8% have relapsing-remitting MS, and 13.5% have secondary progressive MS. FUTURE PLANS: Recruitment will continue over the next 10 years. Genotyping and genetic data quality control are ongoing. Within the next 3 years, we aim to perform initial genetic analyses of susceptibility and severity with a view to replicating the findings from European-ancestry studies. In the long term, genetic data will be combined with other datasets to further cross-ancestry genetic discoveries.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingAdultFemaleGenetic Association StudiesHumansMaleMiddle AgedUnited KingdomGENETICSMultiple sclerosisNeurology

Identifiers

PMID37197821
PMCPMC10193065

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.